You are here

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bronchial Asthma, Obstructive Lung Diseases, Respiratory Tract Diseases, Bronchial Diseases
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects with a physician documented history or diagnosis of persistent asthma for at
least 6 months prior to Screening Visit 1.

Trough FEV1 must be 50-100% of predicted at Screening Visit 1.

Subjects who have been maintained on a stable dose of ICS over the previous month prior to
screening.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects who have had a severe asthma exacerbation in the 2 months prior to screening.

Subjects meeting any of the criteria of 'very poorly controlled' according to the NIH EPR 3
guidelines.

Subjects with evidence or history of cardiovascular disease including angina, myocardial,
infarction, clinically significant cardiac arrhythmia (eg, atrial fibrillation, atrial
flutter,supraventricular tachycardia, ventricular tachycardia), systemic hypertension (SBP
> 160 mmHg or DBP >100mmHg), pulmonary hypertension or cerebrovascular disease (including
transient ischaemic attacks).

NCT00830427
Pfizer
Withdrawn
A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now